Summit Therapeutics Inc. (SMMT) Income Statement Analysis

See more : PT Bundamedik Tbk (BMHS.JK) Income Statement Analysis – Financial Results

Complete financial analysis of Summit Therapeutics Inc. (SMMT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Summit Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Summit Therapeutics Inc. (SMMT)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.summittxinc.com

About Summit Therapeutics Inc.

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	0.00	704.30K	1.81M	860.00K	632.02K	56.41M	35.98M	2.88M	0.00	2.27M	2.27M	2.87M	2.77M	1.21M	301.95K	266.64K	6.03M	2.03M	947.89K	212.76K	1.82K
Cost of Revenue	2.05M	2.51M	0.00	0.00	155.40K	24.92K	97.67K	0.00	0.00	0.00	0.00	0.00	1.01M	0.00	0.00	5.77K	2.51M	596.30K	415.93K	169.46K	1.82K
Gross Profit	-2.05M	-1.81M	1.81M	860.00K	476.62K	56.39M	35.88M	2.88M	0.00	2.27M	2.27M	2.87M	1.77M	1.21M	301.95K	260.87K	3.51M	1.43M	531.96K	43.31K	0.00
Gross Profit Ratio	0.00%	-256.95%	100.00%	100.00%	75.41%	99.96%	99.73%	100.00%	0.00%	100.00%	100.00%	100.00%	63.68%	100.00%	100.00%	97.84%	58.28%	70.60%	56.12%	20.35%	0.00%
Research & Development	59.47M	52.00M	85.35M	53.27M	32.71M	51.38M	41.01M	23.69M	23.94M	15.64M	10.83M	5.72M	4.78M	3.66M	3.68M	7.38M	15.34M	5.79M	1.83M	504.60K	0.00
General & Administrative	30.27M	26.70M	23.61M	19.23M	7.24M	16.19M	16.98M	10.35M	7.45M	6.80M	3.24M	2.77M	2.31M	2.68M	3.83M	3.91M	5.14M	863.07K	1.79M	75.31K	43.79K
Selling & Marketing	-2.05M	0.00	0.00	0.00	2.06M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	372.24K	1.12M	2.17M	1.00M	0.00	0.00	0.00
SG&A	28.22M	26.70M	23.61M	19.23M	9.30M	16.19M	16.98M	10.35M	7.45M	6.80M	3.24M	2.77M	2.31M	2.68M	4.20M	5.03M	7.31M	1.86M	1.79M	75.31K	43.79K
Other Expenses	0.00	-14.42M	-20.97M	-19.31M	0.00	-19.88M	-3.86M	-1.95M	-3.14M	-682.90K	-682.90K	18.95K	339.19K	-10.32M	3.48M	2.97M	2.70M	2.37M	119.60K	0.00	-1.82K
Operating Expenses	87.69M	64.28M	88.00M	53.19M	42.00M	47.69M	54.13M	33.94M	29.45M	19.29M	13.33M	8.51M	7.45M	5.55M	9.49M	15.43M	26.92M	10.03M	3.74M	579.92K	43.79K
Cost & Expenses	89.74M	64.28M	88.00M	53.19M	43.40M	47.69M	54.13M	33.94M	29.45M	19.29M	13.33M	8.51M	7.45M	5.55M	9.49M	15.43M	29.43M	10.62M	4.16M	749.37K	45.61K
Interest Income	10.40M	1.51M	178.95K	4.00K	4.34K	3.66M	4.38M	10.00K	30.00K	0.00	14.85K	17.37K	10.99K	26.90K	12.78K	430.95K	1.54M	1.72M	1.04M	404.81K	1.82K
Interest Expense	16.46M	4.40M	281.00K	255.00K	32.52K	556.10K	1.65M	1.08M	0.00	448.00K	0.00	0.00	4.71K	6.33K	107.04K	116.74K	75.56K	11.77K	0.00	0.00	0.00
Depreciation & Amortization	90.74M	2.51M	2.46M	2.00M	1.39M	1.49M	348.21K	72.50K	68.36K	49.72K	42.89K	146.89K	295.22K	710.54K	3.78M	2.74M	3.28M	737.53K	240.99K	9.41K	1.82K
EBITDA	1.00M	-52.63M	-62.74M	-37.13M	-16.80M	11.66M	-32.19M	-30.98M	-20.30M	-12.20M	-11.02M	-5.48M	-4.41M	-8.65M	-5.41M	-16.03M	-18.58M	-6.13M	-2.97M	-527.20K	-41.96K
EBITDA Ratio	0.00%	-8,633.17%	-4,764.29%	-5,985.47%	-6,546.15%	24.59%	-37.31%	-1,075.82%	0.00%	-854.30%	-486.04%	-191.35%	-157.79%	-298.82%	-1,786.78%	-4,499.47%	-308.42%	-302.42%	-203.69%	-57.52%	-2,300.00%
Operating Income	-89.74M	-72.09M	-86.19M	-53.19M	-42.76M	12.38M	-18.25M	-31.07M	-28.73M	-19.15M	-11.07M	-7.23M	-4.71M	-9.38M	-9.20M	-19.20M	-23.40M	-8.60M	-3.21M	-536.61K	-43.79K
Operating Income Ratio	0.00%	-10,235.63%	-4,764.29%	-6,185.23%	-6,766.39%	21.95%	-50.73%	-1,078.69%	0.00%	-844.40%	-487.93%	-252.32%	-170.09%	-777.06%	-3,047.63%	-7,198.94%	-388.45%	-423.79%	-338.91%	-252.21%	-2,400.00%
Total Other Income/Expenses	-526.14M	-19.15M	-24.87M	-14.01M	-1.04M	-3.30M	1.91M	-854.00K	5.54M	-427.00K	14.85K	17.37K	6.28K	20.57K	-94.26K	314.20K	1.47M	1.71M	1.04M	404.81K	1.82K
Income Before Tax	-615.87M	-78.78M	-88.60M	-52.91M	-28.41M	6.60M	-15.42M	-32.13M	-28.69M	-19.07M	-11.05M	-7.21M	-4.71M	-9.36M	-9.30M	-18.88M	-21.94M	-6.88M	-2.17M	-131.80K	-41.96K
Income Before Tax Ratio	0.00%	-11,185.94%	-4,897.84%	-6,152.33%	-4,494.86%	11.70%	-42.85%	-1,115.76%	0.00%	-841.02%	-487.27%	-251.71%	-169.86%	-775.36%	-3,078.84%	-7,081.10%	-364.13%	-339.36%	-229.12%	-61.95%	-2,300.00%
Income Tax Expense	-946.00K	-4.40M	-2.46M	-213.00K	-4.52M	-3.27M	-5.32M	-5.42M	-4.36M	-1.95M	-1.00M	-538.61K	-477.37K	-1.94M	-594.31K	-2.52M	-1.81M	-959.18K	-278.48K	-45.19K	-1.82K
Net Income	-614.93M	-74.38M	-86.15M	-52.70M	-23.88M	9.87M	-10.09M	-26.71M	-24.34M	-17.12M	-10.05M	-6.67M	-4.23M	-7.42M	-8.66M	-32.29M	-20.13M	-5.92M	-1.89M	-86.61K	-41.96K
Net Income Ratio	0.00%	-10,561.06%	-4,762.13%	-6,127.56%	-3,779.08%	17.50%	-28.05%	-927.56%	0.00%	-754.85%	-443.13%	-232.91%	-152.63%	-614.68%	-2,867.20%	-12,109.76%	-334.06%	-292.07%	-199.74%	-40.71%	-2,300.00%
EPS	-0.99	-0.38	-0.93	-0.76	-0.15	0.11	-0.16	-0.43	-0.41	-0.43	-2.08	-0.42	-0.02	-0.04	-0.13	-0.60	-0.42	-0.16	-0.06	0.00	0.00
EPS Diluted	-0.99	-0.38	-0.93	-0.76	-0.15	0.11	-0.15	-0.43	-0.41	-0.43	-2.08	-0.42	-0.02	-0.04	-0.13	-0.60	-0.42	-0.16	-0.06	0.00	0.00
Weighted Avg Shares Out	619.65M	193.34M	92.24M	69.52M	164.15M	86.14M	65.03M	61.55M	59.10M	39.60M	4.83M	15.81M	177.88M	166.29M	67.01M	53.39M	47.90M	36.42M	31.31M	23.47M	19.02M
Weighted Avg Shares Out (Dil)	619.65M	193.34M	92.24M	69.52M	164.15M	86.14M	65.43M	61.55M	59.10M	39.60M	4.83M	15.81M	177.88M	166.29M	67.01M	53.39M	47.90M	36.42M	31.31M	23.47M	19.02M

Levi & Korsinsky Announces an Investigation on Behalf of Summit Therapeutics Inc. (SMMT) Shareholders Who May Have Been Affected by Fraud

February 28, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning possible violations of federal securities laws. To obtain additional information, go...

Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT

February 28, 2024accesswire.com

Summit Therapeutics Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SMMT

February 27, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning possible violations of federal securities laws. To obtain additional information, go...

ATTENTION Summit Therapeutics Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

February 27, 2024accesswire.com

SMMT ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Summit Therapeutics Inc. Shareholders Who Lost Money

February 26, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / February 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning possible violations of federal securities laws. To obtain additional information, go...

SMMT ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Summit Therapeutics Inc. Shareholders Who Lost Money

February 26, 2024accesswire.com

Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

February 26, 2024businesswire.com

NEW YORK--(BUSINESS WIRE)---- $SMMT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ: SMMT). Investors who purchased Summit securities are encouraged to obtain additional information and...

Levi & Korsinsky Reminds Shareholders of an Investigation into Summit Therapeutics Inc. (SMMT) Regarding Potential Securities Fraud Allegations

February 25, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / February 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning possible violations of federal securities laws. To obtain additional information, go...

Levi & Korsinsky Announces an Investigation on Behalf of Summit Therapeutics Inc. (SMMT) Shareholders Who May Have Been Affected by Fraud

February 23, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / February 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning possible violations of federal securities laws. To obtain additional information, go...